dc.identifier.citation | 1. Sureda A, Bader P, Cesaro S, et al. Indications for allo and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037-1056.
2. Tanyeli A, Aykut G, Demirel AO, Akçaoğlu T. Hematopoetik kök hücre nakli ve tarihçesi. Arşiv Kaynak Tarama Dergisi. 2014;23:1-7.
3. Thomas ED Nathan DG Goldman JM. Classic papers in hematological malignancies: Chronic leukemias. London, New York 2001;139-144.
4. 2015 UPBG. Indications for HSCT in Children 2015.
5. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for
haematological diseases, solid tumours and immune disorders: current practice in
Europe. Bone Marrow Transplantation. 2010;45:219-234.
6. Kansoy S. Türkiye’de pediatrik hematopoietik kök hücre nakilleri. Kansoy S, editör.
Çocuklarda Kök Hücre Nakli. 1. Baskı. Ankara: Türkiye Klinikleri; 2020;1-6.
7. Duarte RF, Labopin M, Bader P, et al. Indıcations for hematopoietic stem cell
transplantation for heematological diseases, solid tumours and immune disorders:
current practice in Europe, Bone Marrow Transplantation. 2019; 54:1525-1552.
8. Hematopoietik kök hücre transplantasyonu pediatrik endikasyonlar, TC Sağlık
Bakanlığı web sitesi, www.saglik.gov.tr, 2023.
9. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and
Allogeneic Hematopoietic Cell Transplantation: Guidelines from American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(11):1863-1869.,
10. Hematopoietik kök hücre transplantasyonu pediatrik endikasyonlar, THD web sitesi, https://www.thd.org.tr/1/haberler/780/hematopoetik-kok-hucre-transplantasyonu- endikasyon-listeleri.
11. Kansoy S. Türkiye’de Ulusal Pediatrik Hematopoetik Kök Hücre Transplantasyon Aktivitesi. 11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi. 2019;25-27.
12. Aksoylar S, Özek G, Akcan M. Verici kaynakları seçimi ve güvenliği. Kansoy S, editör. Çocuklarda Kök Hücre Nakli. 1. Baskı. Ankara: Türkiye Klinikleri; 2020. 18-25.
13. Fuschs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? ASH Education Book 2012;1: 230-236.
68
14.Wang Y, Wu DP, Liu QF, et al. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for hematopoietic transplants. Leukemia. 2018;32: 492-498.
15. Tavil B. Allojenik Hematopoietik Kök Hücre Transplantasyonunda Hazırlık Rejimleri. Arşiv Kaynak Tarama Dergisi.23:32-41.
16. Dündar Yenilmez E, Tuli A. Kemik İliği Transplantasyonunda Kimerizm Analizi. Arşiv Kaynak Tarama Dergisi. 2014;23:26-31.
17. Machaczka M, Kalaitzakis E, Eleborg L, Ljungman P, Hägglund H. Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. Bone Marrow Transplantation. 2010;45:53-61.
18. Kılıçoğlu G. Kök Hücre Toplama Yöntemleri 14. Ulusal Aferez Kongresi 2019.
19. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC
collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant. 2005;35:361- 367.
20. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatric blood & cancer. 2006;46:422-433.
21. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27:689- 692.
22. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringdén O, Wagner JE. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22(24):4872-4880.
23. Valcárcel D, Sureda A. Graft Failure. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019. Chapter 41. PMID: 32091792.
24. Hamerton JL, Harnes DWH. Cytological identification of radiation chimeras. Nature. 1956;177:239-247.
69
25. Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation—an old complication with new insights. Semin Hematol 2019;56 (3):215–20.
26. PrabahranAA,KoldejR,CheeL,RitchieDS.Clinical features, pathophysiology and therapy of poor graft function post allogeneic stem cell transplantation. Blood Adv 2022 Mar 22;6(6):1947–59.
27. Valcarcel D, Sureda A. Graft failure. EBMT Handb Hematop Stem Cell Transplant Cell Ther 2019:307–13.
28. Chen J, Wang H, Zhou J, Feng S. Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol 2020;11. 2040620720948743.
29. LaroccaA,PiaggioG,Podest`aM,etal.AboostofCD34+-selectedperipheralblood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91(7):935–40.
30. Zhao YM, Gao F, Shi JM, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2019;25(9):1898–907.
31. Alchalby H, Yunus D-RR, Zabelina T, Ayuk F, Kro ̈ger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant 2016;51(9):1223–7.
32. Sun YQ, Wang Y, Zhang XH, et al. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol 2019;98(8):1877–83.
33. Bramanti S, Calafiore V, Longhi E, et al. Donor-specific anti-HLA antibodies in Haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes. Biol Blood Marrow Transplant 2019;25(7):1395–406.
34. Wang Y, Kong Y, Zhao H-Y, et al. Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. BMC Med 2022;20(1).
35. PrabahranA,KoldejR,CheeL,WongE,RitchieD.Evaluationofriskfactorsforand subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma 2021;62(6):1482–9.
70
36. Klyuchnikov E, El-Cheikh J, Sputtek A, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant 2014;20(3):382–6.
37. Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor Chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Th. Transplant Cell Ther 2021;27(8):642–9.
38. Wang YU, Liu Q-F, Xu L-P, et al. Haploidentical vs identical- sibling transplant for AML in remission: a multicenter, pro- spective study. Blood. 2015;125(25):3956- 3962.
39. Sun Y-Q, He G-L, Chang Y-J, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanip- ulated haploidentical stem cell transplantation. Ann Hematol. 2015;94(10):1699-1705.
40. Lv W-R, Zhou Y, Xu J, et al. Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single- center retrospective study. Cancer Med. 2021;10:8497– 8506.
41. Hama A, Muramatsu H, Narita A, et al. Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia. Pediatr Transplant. 2020;24:e13828.
42. Lin F, Han T, Zhang Y, et al. The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia. Front. Immunol.2022,13:896034. doi: 10.3389/fimmu.2022.896034
43. Xiao Y, Song J, Jiang Z, Li Y, Gao Y, Xu W, Lu Z, Wang Y, Xiao H. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci. 2014 Apr 30;11(6):652-7.
44. Bensinger WI, Martın PJ, Storer B, et al. Transplantation of the bone marrow compared with peripheral blood cells from HLA-identical relatives in patients with hematological cancers. New Eng J Med. 2001;344:175-181.
45. Shono Y, Ueha S, Wang Y, et al. Bone marrow graft-versus host disease;early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood. 2010;115(26):5401-5411.
71
46. Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftmant of second hematopoietic stem cell allografts (HSCT) in the treatment for primary graft failure. Biol Blood Marrow Transplant. 2010;16(8):1099-1106.
47. Jaspers A, Baron F, Williems E, et al. Erythropoietin therapy after allogenic hematopoietic cell transplantation: a prospective, randomized trial. Blood. 2014;124(1):33-41.
48. Jaspers A, Baron F, Servais S, et al. Erytropoietin therapy after allogenic hematopoietic cell transplantation has no impact on longterm survival. Am J Hematol. 2015;90(9):197-199.
49. Tanaka T, Inamoto Y, Yamashita T, et al. Eltrombopag for treatment of thrombocytopenia after allogenic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(5):919-924.
50. Li Z, Rubinstein SM, Thota R, et al. Immune-mediated complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016, 22:1368–1375.
51. Michniacki TF, Ebens CL, Choi SW. Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies. Curr Oncol Rep. 2019.
52. O’Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 2004.
53. Daikeler T, Labopin M, Ruggeri A, et al. New autoimmune diseases after cord blood transplanta- tion: a retrospective study of EUROCORD and the autoimmune disease working party of the European group for blood and marrow transplantation. Blood. 2013.
54. Faraci M, Zecca M, Pillon M, et al. Autoimmune hematological diseases after alloge- neic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant. 2014.
55. Chang TY, Jaing TH, Wen YC, et al. Risk factor analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in children. Medicine (Baltimore) 95. 2015.
72
56. Hwang-Bo S, Kim SK, Lee JW, et al. Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell trans- plantation in children [Internet]. Blood Res, 2017, 52:119–124.
57. Kruizinga MD, van Tol MJD, Bekker V, et al. Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2019, 24:772– 778.
58. Deambrosis D, Lum SH, Hum RM, et al. Immune cytopenia post-cord transplant in Hurler syndrome is a forme fruste of graft rejection [Internet]. Blood Adv. 2019,3:570–574.
59. Koo J, Giller RH, Quinones R, et al. Autoimmune cytopenias following allo- geneic hematopoietic stem cell transplant in pediatric patients: response to therapy and late effects. Pediatr Blood Cancer 2020, 67.
60. Neely JA, Dvorak CC, Pantell MS, et al. Autoimmune cytopenias in pediatric hematopoietic cell transplant patients. Front Pediatr. 2019,7.
61. Lum SH, Selvarajah S, Deya-Martinez A, et al. Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency. J Allergy Clin Immunol. 2020,146:406–416.
62. Miller PDE, Snowden JA, De Latour RP, et al. Autoimmune cytopenias (AIC) following allogeneic hae- matopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant.2020,55:441–451.
63. Szanto CL, Langenhorst J, de Koning C, et al. Predictors for autoimmune cytopenias after allogeneic hematopoietic cell trans- plantation in children. Biol Blood Marrow Transplant.2020,26:114–122.
64. Ahmed I, Teruya J, Murray-Krezan C, Krance R. The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post- second hematopoietic stem cell transplant. Pediatr Transplant. 2015,19:391–398.
65. Page KM, Mendizabal AM, Prasad VK, et al. Post- transplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unre- lated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant.2015,14:1108–1117.
73
66. Bhatt V, Shune L, Lauer E, et al. Autoimmune hemolysis and immune thrombocyto- penic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab. Bone Marrow Transplant.2016,51:1579–1583.
67. González-Vicent M, Sanz J, Fuster JL, et al. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): a retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). Transfus Med Rev.2018,32:179– 185.
68. Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract & Res Clin Haematol.2017,20:349–360
69. Ueki H, Igarashi S, Kimura S, Tsuchimochi T,et al. Evans syndrome after unrelated bone marrow transplantation for refractory cytope- nia of childhood [Internet]. Pediatr Transplant.2014,18:E246–E251.
70. Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol.2021,8:e229–e239.
71. Manuela S, Francesco S, Valeria C, et al. European Journal of Pediatrics, 2023,182:2471–2483.
72. Gupta AO, Jan Boelens J, Ebens CL, et al. Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disor- ders [Internet]. Bone Marrow Transplant.2021,56:1238–1247.
73. Yanir AD, Hanson IC, Shearer WT, et al. High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease [Internet]. Biol Blood Marrow Transplant.2021,24:1643–1650.
74. Galvin RT, Cao Q, Miller WP, Knight-Perry J, Smith AR, Ebens CL. Characterizing immune-mediated cytopenias after allogeneic hematopoietic cell transplantation for pediatric non- malignant disorders. Transplant Cell Ther.2021,27(316):e1-316.e8
75. Gabelli M, Ademokun C, Cooper N, Amrolia PI.Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting [Internet]. Br J Haematol.2022,196:45–62.
76. Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation [Internet]. Hematol Am Soc Hematol Educ Progr.2015,378–384.
74
77. Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips GL, Liesveld J. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia [Internet]. Am J Hematol.2012, 87:743–745.
78. Masetti R, Vendemini F, Quarello P, et al. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children. Pediatr Blood Cancer 2020,67.
79. Beck JC, Burke MJ, Tolar J. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim. Pediatr Blood Cancer.2010,54:490–491.
80. Bento L, Bastida JM, García-Cadenas I, et al. Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: expe- rience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant.2019,25:1825–1831.
81. Deng J, Zhou F, Wong CY, Huang E, Zheng E. Efficacy of therapeutic plasma exchange for treatment of autoimmune hemolytic anemia: a systematic review and meta-analysis of ran- domized controlled trials. J Clin Apher.2020,35:294–306.
82. Cwynarski K, Goulding R, Pocock C, et al. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leu- kaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant.2021,28:581–586.
83. Herrera AF, Kim HT, Bindra B, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant.2014,20:1737–1743.
84. Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemo- lytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018, 2:2550–2553.
85. Hess J, Su L, Nizzi F, et al. Successful treatment of severe refractory autoimmune hemolytic anemia after hemat- opoietic stem cell transplant with abatacept. Transfusion. 2018, 58:2122–2127.
86. Even-Or E, Naser Eddin A, Shadur B, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer, 2020, 67.
87. Vitale C, Ahn IE, Sivina M, Ferrajoli A, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica.2017,101:e254–e258.
75
88. Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 2016,30:346–350.
89. Teusink-Cross A, Davies SM, et al. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: a singlecenter experience. Pediatr Transplant. 2020.
90. Kansu E. Kök Hücre Naklinden Sonra Görülen Graft-Versus Host Hastalığı. Türk Hematoloji Derneği, Kan ve Kemik İliği Transplantasyon Kursu.
91. Man Y, Lu Z, Yao X, et al. Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation. Front. Immunol. 13:911174.
92. Nakamae H, Storer B, Sandmaier BM, et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011;96(12):1838-1845.
93. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allo- geneic marrow transplant recipients receiv- ing ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90(6):2502-2508.
94. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88(10): 4063-4071.
95. Khalil MAM, Khalil MAU, Khan TFT, Tan J. Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. J Transplant. 2018 Aug 1;2018:9429265.
96. Barry M, Chandra S, Hymes KB. Cytopenias in Transplant Patients. Principles and Practice of Transplant Infectious Diseases. 2018 Dec 8:199–207.
97. Page KM, Mendizabal AM, Prasad VK, et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2008 Oct;14(10):1108-1117.
98. Buxbaum NP and Pavletic SZ (2020) Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation. Front. Immunol. 11:2017.T | tr_TR |